Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.

The gilead lawsuit update 2026 shows thousands of claims against Gilead Sciences still moving through federal court. Plaintiffs allege the company knowingly sold dangerous TDF-based HIV drugs while sitting on a safer alternative for years. If you took Truvada, Atripla, Viread, Complera, or Stribild and suffered kidney or bone damage, this year could bring major developments in your case.

Roughly 26,000 lawsuits have been filed under MDL No. 2881 in the Northern District of California. Bellwether trial outcomes from 2024 and 2025 have set the stage for possible mass settlement talks in 2026.

This article covers everything you need to know right now. We break down settlement estimates, payout ranges, eligibility rules, filing deadlines, and what the latest court rulings mean for your claim.

Also worth exploring: Live Olympics Lawsuit 2026: Settlement and Filing Update

Some plaintiffs could see individual payouts ranging from $50,000 to over $500,000 depending on injury severity. The clock is ticking on filing deadlines, so read every section carefully.

Gilead Lawsuit Update 2026: Where Things Stand Now

The Gilead lawsuit in 2026 is entering what many legal observers consider its most consequential phase yet. After years of pretrial motions, bellwether trials, and procedural battles, the litigation is moving toward broader resolution.

As of early 2026, MDL No. 2881 remains centralized before Judge Jon S. Tigar in San Francisco. The court has been managing discovery, coordinating trial schedules, and overseeing mediation efforts between plaintiff attorneys and Gilead’s defense team.

Several bellwether verdicts from prior years have given both sides a clearer picture of how juries respond to the core allegations. Those results now serve as negotiation benchmarks.

The primary allegation has not changed. Plaintiffs say Gilead Sciences had a safer drug compound called TAF (tenofovir alafenamide) ready years before it reached patients. Instead, the company kept selling TDF-based drugs that carry higher risks of kidney damage and bone density loss.

2026 could be the year the dam breaks on settlements. Both sides have reasons to want resolution. Gilead faces mounting legal costs, and plaintiffs want compensation before statutes of limitations become a factor for newer claims.

Gilead Sciences Lawsuit 2026: The Full Picture

The Gilead Sciences lawsuit in 2026 represents one of the largest pharmaceutical mass torts in recent U.S. history. At its core, this case is about corporate greed and delayed innovation.

Gilead Sciences is a major biopharmaceutical company headquartered in Foster City, California. It developed some of the most widely prescribed HIV prevention and treatment drugs in the world. Millions of people worldwide have taken its medications.

The problem is straightforward. Gilead’s TDF-based drugs, while effective against HIV, cause serious side effects in the kidneys and bones. Internal company research allegedly showed that a newer compound, TAF, worked just as well with significantly fewer side effects.

• Gilead patented TDF in 2001 and began selling it in drugs like Viread
• The company allegedly had TAF data as early as 2001 but shelved development
• TAF was not brought to market until 2015 with the drug Genvoya
• During that 14-year gap, millions of patients took TDF-based medications
• Many suffered irreversible kidney and bone injuries

Plaintiffs argue that Gilead delayed TAF solely to maximize profits from TDF drug patents. When TDF patents neared expiration, Gilead suddenly “discovered” TAF was viable and launched new products to maintain market exclusivity.

That’s the kind of corporate behavior that makes juries angry. And it’s exactly why bellwether trial results have favored plaintiffs.

Gilead Truvada Lawsuit Settlement Amounts in 2026

Gilead Truvada lawsuit settlement amounts in 2026 have not been publicly finalized as of this writing. However, legal analysts and plaintiff attorneys have been projecting ranges based on bellwether verdicts and comparable pharmaceutical settlements.

The first bellwether trials resulted in mixed outcomes. Some juries awarded significant damages to plaintiffs, while Gilead won other cases. That back-and-forth is typical in mass tort litigation and usually pushes both sides toward settlement negotiations.

Based on prior pharmaceutical mass tort settlements and the severity of injuries in this case, here are projected ranges:

These numbers are projections, not guarantees. Each case depends on individual medical records, duration of TDF drug use, and the strength of causation evidence.

What’s clear is that plaintiffs with documented renal damage and long-term TDF exposure have the strongest claims. Cases involving younger patients who developed chronic kidney disease carry especially high value.

Settlement talks in 2026 could establish a formal grid system where payouts are assigned based on injury tier, age at diagnosis, and length of drug use.

Key Takeaway: Settlement amounts in the Gilead lawsuit will vary widely based on the severity of your injury, but projections suggest payouts between $50,000 and over $1 million for the most serious cases.

Truvada Lawsuit Payout Per Person in 2026

The Truvada lawsuit payout per person in 2026 depends on several individual factors. No flat per-person figure applies to everyone.

Think of it like car insurance claims. A fender bender pays differently than a totaled vehicle. The same logic applies here. A plaintiff who developed mild bone thinning will receive far less than someone on dialysis.

That said, plaintiff attorneys have publicly discussed expected ranges. For cases with strong medical documentation, individual payouts could reach six figures or higher.

Factors that affect your payout:

• Type of injury: Kidney failure pays more than bone density loss
• Severity: Chronic conditions pay more than temporary side effects
• Duration of TDF use: Longer exposure strengthens the claim
• Age at injury: Younger patients with decades of health impact get more
• Medical documentation: Lab results, biopsies, and doctor records matter
• Which drug you took: Truvada, Atripla, Viread, Complera, or Stribild

Plaintiffs who can show a direct link between their TDF medication and their diagnosis are in the best position. If your doctor has documented declining kidney function during the period you took one of these drugs, that’s strong evidence.

One important note: any global settlement will likely include attorney fees and litigation costs subtracted from your payout. Most contingency arrangements take 33% to 40% of the total award.

Gilead HIV Drug Lawsuit Status in 2026

The Gilead HIV drug lawsuit status in 2026 is active and advancing toward potential resolution. This is not a dead case or a stalled docket. Real movement is happening.

After bellwether trials concluded in 2024 and 2025, the MDL court has shifted focus toward case management of the broader plaintiff pool. Judge Tigar has been working with both parties to explore global settlement frameworks.

Here is the litigation status broken down by phase:

The MDL structure means individual lawsuits from across the country are handled together for pretrial purposes. This saves time and ensures consistency. Once a settlement or verdict framework is established, individual cases get resolved through that system.

Gilead has indicated it will continue to defend itself vigorously. But the financial pressure of ongoing litigation with 26,000 plaintiffs creates strong incentive to settle.

For plaintiffs, the wait has been long. Many filed claims years ago. But 2026 brings genuine hope that resolution is within reach.

Who Qualifies for the Gilead Lawsuit in 2026?

You may qualify for the Gilead lawsuit in 2026 if you took a TDF-based HIV medication and later developed kidney problems or bone density loss. That is the core eligibility standard.

The lawsuit covers five specific medications manufactured by Gilead Sciences:

• Truvada (emtricitabine/tenofovir DF)
• Atripla (efavirenz/emtricitabine/tenofovir DF)
• Viread (tenofovir DF)
• Complera (emtricitabine/rilpivirine/tenofovir DF)
• Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir DF)

If you took any of these medications for HIV treatment or PrEP (pre-exposure prophylaxis) and experienced health problems, you likely have a valid claim.

You may qualify if you experienced any of these conditions:

• Chronic kidney disease
• Acute kidney injury
• Renal tubular dysfunction
• Fanconi syndrome
• Kidney failure requiring dialysis
• Kidney transplant
• Osteoporosis or osteopenia
• Bone fractures related to density loss
• Tooth loss due to bone deterioration

Both HIV-positive patients and HIV-negative individuals who used Truvada for PrEP are eligible. The lawsuit is not limited by HIV status. It is about the drug’s side effects, not the patient’s underlying condition.

Key Takeaway: If you took Truvada, Atripla, Viread, Complera, or Stribild and suffered kidney or bone injuries, you likely qualify to file a claim in the Gilead lawsuit, regardless of your HIV status.

Gilead Lawsuit Eligibility Requirements

Gilead lawsuit eligibility requirements involve proving three things: you took a TDF drug, you suffered a qualifying injury, and the two are connected.

This is the standard product liability formula. You need the product, the harm, and the link between them. Without all three, the claim falls apart.

Here is a clearer breakdown:

Proof of drug use can come from pharmacy records, prescription history, insurance claims, or medical chart notes. Your doctor’s office or health insurer should have these records.

Qualifying injuries must be documented by a physician. Lab results showing elevated creatinine, low GFR (glomerular filtration rate), or DEXA scan results showing bone mineral density loss are commonly used as evidence.

Causation is the trickiest part. Your medical records need to show a timeline where kidney or bone problems appeared during or shortly after TDF medication use. If you had pre-existing kidney disease before starting the medication, your claim may face challenges.

The statute of limitations varies by state. Some states allow only two years from the date of diagnosis to file. Others allow longer. Check your state’s specific deadline, because missing it means losing your right to compensation permanently.

Gilead MDL 2881 Update for 2026

The Gilead MDL 2881 update for 2026 shows the multidistrict litigation remains active and is transitioning from trial phases into potential settlement discussions.

MDL 2881 was created in 2019 when the Judicial Panel on Multidistrict Litigation consolidated thousands of Gilead TDF lawsuits into one court. The Northern District of California was selected, with Judge Jon S. Tigar presiding.

The purpose of an MDL is efficiency. Instead of 26,000 separate lawsuits clogging courts across the country, one judge handles shared pretrial issues. Discovery, expert witness challenges, and procedural motions all happen once.

Key MDL 2881 milestones:

• 2019: MDL created, cases consolidated in N.D. California
• 2020 to 2022: Massive discovery phase, millions of Gilead documents reviewed
• 2022 to 2023: Daubert hearings on scientific expert testimony
• 2023 to 2025: Bellwether trials conducted
• 2026: Post-bellwether evaluation and settlement framework discussions

The bellwether process is essentially a test run. A small group of representative cases goes to trial so both sides can gauge how juries react. Those results inform settlement values.

In 2026, the MDL court is expected to push harder for global resolution. Judge Tigar has signaled interest in moving the docket forward rather than letting cases linger for years more.

Don't miss this — Education Lawsuit Last Week: 2026 Payout and Filing Guide

If settlement negotiations succeed, individual plaintiffs will receive offers based on a predetermined grid. If talks fail, cases could be remanded back to their original courts for individual trials.

Gilead TDF Lawsuit Timeline for 2026

The Gilead TDF lawsuit timeline for 2026 marks roughly seven years since the MDL was established. Here is a year-by-year breakdown of how this litigation has progressed and what comes next.

The 14-year gap between TDF and TAF availability is the heart of this case. Plaintiffs argue that every year of that gap represents preventable harm to patients.

For 2026 specifically, the expected timeline includes continued mediation sessions, possible announcement of a settlement framework by mid-year, and initial claim processing by late 2026 if a deal is reached.

If no settlement occurs, the court could schedule additional trials. But most legal experts believe the volume of cases and the financial stakes make a negotiated resolution far more likely than 26,000 individual trials.

Key Takeaway: The Gilead TDF lawsuit has been building since 2018, and 2026 represents the most likely window for a global settlement framework that could begin resolving thousands of pending claims.

Gilead Lawsuit Bellwether Trial Results

Gilead lawsuit bellwether trial results have been mixed, with some significant plaintiff wins and some Gilead victories. This pattern is actually common in major pharmaceutical litigation.

Bellwether trials serve as test cases. A handful of representative plaintiffs go to trial before a jury. The outcomes help both sides understand how strong their arguments really are when put before everyday people.

In the Gilead MDL, bellwether cases focused on plaintiffs who took Truvada or other TDF drugs and developed serious kidney injuries. The key legal question in each trial was whether Gilead knew TAF was safer and deliberately withheld it.

Notable bellwether outcomes:

• Some juries found Gilead liable and awarded compensatory damages in the millions
• Other juries sided with Gilead, finding insufficient proof of causation
• Punitive damages were sought in several cases based on allegations of intentional delay
• Expert testimony about Gilead’s internal documents proved highly persuasive when admitted

The plaintiff victories showed that juries are receptive to the core argument: Gilead had a safer drug and chose profits over patient safety. The Gilead victories showed that causation, meaning proving the drug specifically caused a given plaintiff’s injury, remains a battleground.

For the broader plaintiff pool, these results are a net positive. When a defendant loses even some bellwether trials in a mass tort, the pressure to settle increases dramatically. No company wants to risk hundreds of multi-million dollar verdicts.

Gilead TAF vs TDF Delay Allegations

The Gilead TAF vs TDF delay allegations form the backbone of every lawsuit in this MDL. Plaintiffs claim Gilead had the science to bring a safer drug to market years earlier but chose not to.

Here is the difference between the two compounds:

Internal Gilead documents, obtained during discovery, allegedly show that company scientists were researching TAF as far back as 2001. Some documents suggest early clinical data showed TAF was gentler on kidneys.

The critical question is why Gilead waited until 2015. Plaintiffs say the answer is money. TDF drugs like Truvada were generating billions in annual revenue. Releasing TAF would cannibalize those sales and create a shorter patent window.

By waiting until TDF patents neared expiration, Gilead allegedly got the best of both worlds: maximum TDF profits followed by a fresh patent cycle with TAF drugs. Patients paid the price with their health.

This argument hits hard in courtrooms because it is easy to understand. You had the safer version. You hid it. People got hurt. That’s a story any jury can follow.

Gilead Truvada Kidney Damage Lawsuit

The Gilead Truvada kidney damage lawsuit centers on evidence that TDF is toxic to the renal tubular cells in the kidneys. This is not a speculative claim. It is documented in medical literature and even in the drug’s own FDA labeling.

TDF works by converting into tenofovir in the bloodstream. The problem is that TDF delivers high concentrations of tenofovir to the kidneys. Over time, this can damage the proximal renal tubules, which are critical for filtering waste.

Kidney conditions linked to TDF-based drugs:

• Acute kidney injury
• Chronic kidney disease (stages 3 through 5)
• Renal tubular dysfunction
• Fanconi syndrome (a rare but serious tubular disorder)
• Kidney failure requiring dialysis
• Need for kidney transplant

Some patients showed early warning signs like elevated creatinine and protein in the urine. Others experienced sudden kidney failure after years of seemingly stable use.

The lawsuits argue that Gilead’s own clinical trials showed kidney toxicity signals. Company scientists allegedly flagged these concerns internally. But Gilead continued marketing TDF drugs without adequate warnings and without offering the TAF alternative it had in development.

For plaintiffs with documented kidney damage, these cases are among the strongest in the MDL. Medical records showing declining GFR during TDF use create a clear causation timeline.

Key Takeaway: Kidney damage claims, especially those involving dialysis, Fanconi syndrome, or transplant, represent the highest-value cases in the Gilead lawsuit and carry the strongest evidence of drug-related harm.

Gilead Bone Density Loss Lawsuit Claims

Gilead bone density loss lawsuit claims allege that TDF-based medications cause measurable decreases in bone mineral density. This can lead to osteoporosis, fractures, and lasting skeletal damage.

Bone density loss from TDF is well-documented in clinical studies. The drug affects how the body processes phosphorus and calcium, both essential for maintaining bone strength.

How TDF impacts bones:

• TDF can cause phosphorus wasting through the kidneys
• Lower phosphorus levels lead to bone demineralization
• Patients on long-term TDF therapy show measurable drops in DEXA scan scores
• Some develop osteoporosis, even at younger ages
• Fragility fractures (hip, spine, wrist) have been reported

The bone claims are particularly significant for younger plaintiffs. A 30-year-old developing osteoporosis faces decades of complications including fracture risk, chronic pain, and mobility limitations.

Plaintiffs with DEXA scan results from before, during, and after TDF use have the clearest evidence. If your bone density was normal before Truvada and declined during treatment, that data tells the story for you.

These claims often pair with kidney damage claims. Many plaintiffs experienced both. When you can show two major organ systems were harmed by the same drug, the case value increases substantially.

Gilead HIV Medication Side Effects Lawsuits

Gilead HIV medication side effects lawsuits cover the full range of harm caused by TDF-based antiretroviral drugs. While kidney and bone injuries are the most common, other serious side effects have been reported.

The lawsuits are not claiming that HIV drugs should not exist. Nobody disputes that antiretroviral therapy saves lives. The claim is specific: Gilead had a safer formulation and withheld it, exposing patients to unnecessary risks.

Side effects commonly cited in Gilead lawsuits:

• Kidney damage (most common claim)
• Bone density loss and osteoporosis
• Fanconi syndrome
• Lactic acidosis (rare but serious)
• Liver toxicity in some patients
• Tooth decay and tooth loss (linked to bone density changes)
• Chronic fatigue related to kidney dysfunction

The tooth loss claims have gained attention recently. Dental damage connected to bone mineral density changes in the jaw has become a recognized complication. Some plaintiffs have lost multiple teeth and required extensive dental reconstruction.

For the purposes of this lawsuit, the most legally significant side effects are those that match the known toxicity profile of TDF and that would have been avoided or reduced by timely use of TAF.

This distinction matters because Gilead’s defense often argues that some side effects are related to HIV itself, not the medication. Plaintiffs counter that the specific pattern of proximal renal tubular toxicity and bone demineralization is a TDF signature, not an HIV signature.

Before you go further, consider reading Finance Lawsuit April 2026: Settlement and Payout Updates

How to File a Gilead Lawsuit Claim in 2026

Filing a Gilead lawsuit claim in 2026 is still possible, but the process requires specific documentation and timely action. The window is narrowing as statutes of limitations approach in several states.

Here is a step-by-step overview of the filing process:

Step 1: Gather Your Medical Records
Collect all records related to your TDF drug prescriptions and any kidney or bone diagnoses. Include pharmacy records, lab results, imaging studies, and doctor notes.

Step 2: Identify Your Medications
Confirm which Gilead drug you took. Check old prescription bottles, pharmacy printouts, or insurance claim records for drug names like Truvada, Atripla, Viread, Complera, or Stribild.

Step 3: Document Your Injuries
Get current medical documentation of your condition. A recent GFR test, creatinine panel, or DEXA scan helps establish the ongoing nature of your injury.

Step 4: Contact a Mass Tort Attorney
You need a lawyer who handles pharmaceutical mass tort cases. Most work on contingency, meaning no upfront cost. They only get paid if you win or settle.

Step 5: Case Evaluation and Filing
Your attorney reviews your records, determines case strength, and files the complaint. New cases are typically transferred into MDL 2881.

Do not wait until late 2026 to start this process. Record gathering alone can take weeks or months. Starting early gives your attorney time to build the strongest possible case.

Key Takeaway: Filing a Gilead lawsuit claim in 2026 is a straightforward process, but it requires medical records, proof of drug use, and an attorney who specializes in mass tort litigation; starting early is critical.

Gilead Lawsuit Settlement Deadline in 2026

The Gilead lawsuit settlement deadline in 2026 has not been formally announced because a global settlement framework has not yet been finalized. However, multiple deadlines are in play that could affect your ability to participate.

Statutes of limitations are the most important deadlines. These are state laws that set a time limit on how long you have to file a lawsuit after discovering your injury. They vary significantly:

The clock usually starts ticking when you knew or should have known that your injury was related to the medication. This is called the “discovery rule.” It does not always start from the date you took the drug.

If a global settlement is announced in 2026, there will likely be a separate deadline to submit claims. These claim filing periods typically run 90 to 180 days from the announcement date.

Missing either deadline, whether the statute of limitations or a claim submission window, could permanently bar you from receiving compensation.

Here’s the smart move. If you have not already filed, talk to an attorney now. Even if a settlement deadline has not been set, getting your case into the system protects your rights.

Gilead Class Action Lawsuit 2026

The Gilead class action lawsuit in 2026 is technically not a traditional class action. It is a mass tort organized as a multidistrict litigation, or MDL. The distinction matters.

In a class action, one lawsuit covers everybody. Every class member gets the same outcome, usually a small payout. In a mass tort MDL, each plaintiff has their own individual case. Your payout depends on your specific injuries and evidence.

This is actually better for Gilead plaintiffs. Here is why:

MDL 2881 treats every plaintiff as an individual. Your kidney failure claim is evaluated on its own merits, not lumped in with someone who had mild bone thinning.

This structure means higher potential payouts but a longer process. Each case needs its own documentation and evaluation. That is why the litigation has taken years.

Some people still call it a “class action” colloquially, and that is fine. But knowing it is an MDL helps you understand why your case is evaluated individually and why settlement amounts vary so widely between plaintiffs.

The bottom line: your injuries, your records, and your drug history determine your outcome. Not someone else’s case.

Key Takeaway: The Gilead litigation is a mass tort MDL, not a class action, which means each plaintiff’s case is evaluated individually and payouts can be significantly higher than in a typical class action settlement.

Frequently Asked Questions

How much money will I get from the Gilead Truvada lawsuit in 2026?

Most estimates project individual payouts between $50,000 and $500,000 depending on injury severity.
Cases involving kidney failure, dialysis, or transplant could exceed $1 million.
Exact amounts depend on your medical records, drug history, and the final settlement framework.

Can I still file a Gilead lawsuit claim in 2026?

Yes, new claims are still being accepted in 2026 for most plaintiffs.
You must file before your state’s statute of limitations expires.
Contact a mass tort attorney as soon as possible to protect your filing rights.

What drugs are included in the Gilead TDF lawsuit?

Five Gilead medications are covered: Truvada, Atripla, Viread, Complera, and Stribild.
All contain tenofovir disoproxil fumarate (TDF) as an active ingredient.
Both HIV treatment patients and PrEP users are included.

What injuries qualify for the Gilead lawsuit?

Qualifying injuries include chronic kidney disease, kidney failure, Fanconi syndrome, bone density loss, osteoporosis, and related fractures.
Tooth loss linked to bone deterioration may also qualify.
You need medical documentation connecting the injury to your TDF drug use.

When will Gilead lawsuit settlements be paid out?

Settlement payouts could begin in late 2026 or early 2027 if a global settlement framework is reached.
The exact timeline depends on the pace of negotiations between plaintiff attorneys and Gilead.
Individual case evaluations and claim processing will add additional time after any deal is announced.

The Gilead lawsuit in 2026 is at a turning point. Years of litigation have built the foundation for potential mass resolution that could put real money in the hands of people harmed by TDF-based drugs.

If you took Truvada, Atripla, Viread, Complera, or Stribild and suffered kidney or bone damage, now is the time to act. Gather your medical records, confirm your drug history, and speak with an attorney who handles Gilead TDF cases.

The window for filing is open, but it will not stay open forever. Protect your claim before deadlines pass.

META BLOCK
Meta Title: Gilead Lawsuit Update 2026: Settlements and Key Dates
Meta Title Chars: 55/59
Meta Desc: Get the latest gilead lawsuit update 2026 with settlement amounts, payout estimates per person, eligibility details, MDL status, and key filing deadlines.
Meta Desc Chars: 153/159
Focus Keywords: gilead lawsuit update 2026, gilead truvada lawsuit settlement amounts 2026, truvada lawsuit payout per person 2026, gilead mdl 2881 update, who qualifies for gilead lawsuit
Slug: /gilead-lawsuit-update-2026/

PHASE 5: IMAGE PROMPTS

Image Prompt 1 (Hero Banner):
A professional editorial-style legal banner in horizontal landscape format at 1920×1080 pixels. The bold headline text “Gilead Lawsuit Update 2026” appears prominently in large white serif typography positioned on the left side of the image, with a gold underline accent. The background features a deep navy blue gradient with an abstract silhouette of a federal courthouse and a stylized gavel icon on the right side. Subtle document pages and pill capsule silhouettes float in the background behind a frosted glass overlay. The mood is serious, authoritative, and urgent. Clean modern design with high contrast. Color palette uses deep navy, crisp white, and warm gold accents. No real human faces. No watermarks. No logos. No stock photo feel. Professional Bloomberg Law aesthetic.

Alt Text 1: Gilead lawsuit update 2026 hero banner with courthouse silhouette and gavel icon on navy background

Image Prompt 2 (Supporting Image):
A professional in-article infographic-style visual in horizontal landscape format at 1920×1080 pixels. The bold headline text “Gilead Settlement Amounts 2026” appears centered at the top in clean white sans-serif typography over a deep navy banner strip. Below, the image shows a stylized settlement tier chart with four ascending gold bar graph columns representing different injury categories from mild to severe. Abstract pill capsule icons and kidney organ silhouettes appear subtly in the background. A document with a checkmark icon sits in the lower right corner. The design is clean, modern, and data-driven. Color palette uses deep navy, white, and gold accents. High contrast. No real human faces. No watermarks. No logos. Professional Reuters legal section aesthetic with breathing room on the left side for optional text overlay.

Alt Text 2: Gilead settlement amounts 2026 infographic showing payout tiers by injury category

Along the same lines: Reed-Nelson Lawsuit 2026: Settlement and Payout Guide

Never Miss a Lawsuit Update

Mark Lawfold as a Preferred Source so you never miss a settlement deadline or new filing.